{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:29:54Z","timestamp":1787142594896,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.nefroe.2026.501532","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:44:06Z","timestamp":1787139846000},"page":"501532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium zirconium cyclosilicate for renin\u2013angiotensin\u2013aldosterone system inhibitor therapy optimization: A systematic review and meta-analysis with meta-regression"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8648-4254","authenticated-orcid":false,"given":"Hamlet","family":"Ghukasyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Abraham","family":"Batista da Hora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Rubab","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kau\u00ea","family":"Abreu Chagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taguhi","family":"Hayrapetyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Casas Todol\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Llopis Sanchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felemez","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2026.501532_bib0155","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","article-title":"Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis","volume":"39","author":"Kovesdy","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2026.501532_bib0160","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2026.501532_bib0165","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008912","article-title":"Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes","volume":"7","author":"Thomsen","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nefroe.2026.501532_bib0170","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012655","article-title":"Real-world associations of renin\u2013angiotensin\u2013aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom","volume":"8","author":"Linde","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nefroe.2026.501532_bib0175","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501532_bib0180","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrneph.2014.168","article-title":"Management of hyperkalaemia in chronic kidney disease","volume":"10","author":"Kovesdy","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefroe.2026.501532_bib0185","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13941","article-title":"Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions","volume":"75","author":"Tafesse","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.nefroe.2026.501532_bib0190","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin\u2013angiotensin\u2013aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.nefroe.2026.501532_bib0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12882-022-03054-5","article-title":"Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia","volume":"24","author":"Kanda","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2026.501532_bib0200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejim.2023.08.022","article-title":"Novel potassium binders to optimize RAASi therapy in heart failure: a systematic review and meta-analysis","volume":"119","author":"Paolillo","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.nefroe.2026.501532_bib0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jcm10235483","article-title":"Optimization of RAASi therapy with new potassium binders for patients with heart failure and hyperkalemia: rapid review and meta-analysis","volume":"10","author":"Montagnani","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.nefroe.2026.501532_bib0210","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ehf2.14588","article-title":"The efficacy and safety of new potassium binders on renin\u2013angiotensin\u2013aldosterone system inhibitor optimization in heart failure patients: a systematic review and meta-analysis","volume":"11","author":"Abuelazm","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.nefroe.2026.501532_bib0215","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.nefroe.2026.501532_bib0220","series-title":"Cochrane handbook for systematic reviews of interventions, version 6.3","year":"2022"},{"key":"10.1016\/j.nefroe.2026.501532_bib0225","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.nefroe.2026.501532_bib0230","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.nefroe.2026.501532_bib0235","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40620-023-01743-4","article-title":"Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin\u2013angiotensin\u2013aldosterone system inhibitors: a retrospective observational study","volume":"37","author":"Kimura","year":"2024","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2026.501532_bib0240","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae021","article-title":"Mortality and hyperkalaemia-associated hospitalisation in patients with chronic kidney disease: comparison of sodium zirconium cyclosilicate and sodium\/calcium polystyrene sulfonate","volume":"17","author":"Onogi","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2026.501532_bib0245","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae083","article-title":"Maintained renin\u2013angiotensin\u2013aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study","volume":"17","author":"Rastogi","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2026.501532_bib0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112413","article-title":"Sodium zirconium cyclosilicate (Lokelma) to enable ACEIs\/ARBs use in the treatment of patients with diabetic kidney disease","volume":"227","author":"Hao","year":"2025","journal-title":"Diab Res Clin Pract"},{"key":"10.1016\/j.nefroe.2026.501532_bib0255","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jacc.2024.11.014","article-title":"Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure","volume":"85","author":"Kosiborod","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nefroe.2026.501532_bib0260","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ehf2.14268","article-title":"Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure","volume":"10","author":"Tardif","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.nefroe.2026.501532_bib0265","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","year":"2025","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2026.501532_bib0275","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/ndt\/gfx312","article-title":"Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes \u2013 a Danish population-based cohort study","volume":"33","author":"Thomsen","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2026.501532_bib0280","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/phar.1906","article-title":"Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia","volume":"37","author":"Meaney","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.nefroe.2026.501532_bib0285","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2026.501532_bib0290","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2026.501532_bib0295","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2026.501532_bib0300","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.rce.2020.11.009","article-title":"Consensus on the management of hyperkalemia in patients with heart failure: recommendations from the SEC-SEMI","volume":"222","author":"Almenar Bonet","year":"2022","journal-title":"Rev Clin Esp"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251426001513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251426001513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:44:30Z","timestamp":1787139870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251426001513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2013251426001513"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2026.501532","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium zirconium cyclosilicate for renin\u2013angiotensin\u2013aldosterone system inhibitor therapy optimization: A systematic review and meta-analysis with meta-regression","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2026.501532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501532"}}